“The medical industry is facing unprecedented challenges. Great ideas must become commercial products and services as quickly as possible.” Doug Given
Doug is the managing partner of G5 Partners, which provides strategic advisory services, corporate development, and venture investment in innovative healthcare companies.
Doug’s investing success comes from finding outstanding entrepreneurs and unlocking the value in truly disruptive ideas and breakthrough technologies.
Doug provides expertise in biotechnology, biopharmaceuticals, specialty medical products, and healthcare innovation. He has served on more than 20 public and private boards.
To date, Doug has founded or operated five biotech companies, three of which have become public. He has built teams capable of turning innovative ideas into commercial products and services.
As an internist and infectious diseases doctor with a PhD in virology who also earned his MBA, Doug possesses deep expertise in biotechnology, biopharmaceuticals, specialty medical products, and healthcare innovation. That said, there’s a great deal more to Doug than his career accomplishments.
“Working with Doug as an Investment Partner at Bay City, I was impressed by his keen ability to promptly distinguish excellent concepts that were both actionable and had the potential to become life-altering for patients, whether in the realm of therapeutics, devices, diagnostics or services.”
Mike Perry, DVM, PhD, FRCVS
Chief Scientific OfficerNovartis Pharmaceuticals, Stem Cell and Gene Therapy
“As Chair of the Visiting Committee for the University of Chicago Medical Center, Doug brought an entrepreneurial mindset and strong business acumen that helped shape my team’s reasoning as we raised an unprecedented $885M, rebuilt the BioMedicine campus and recruited scores of world-class academic leaders.”
James Madara, MD, CEO
American Medical Association
“Doug is an extremely valuable advisor and effective board Chair. The breadth of his expertise spans basic science, clinical development, strategy, finance, and operations. His contributions in each of these areas have made a hugely positive impact on our business — and on me personally.”
Christopher Anzalone, PhD, CEO
Arrowhead Research Corporation